OSLO, Norway, Oct. 12, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators will present data and analyses from its non-clinical and clinical studies with Betalutin® (177Lu-lilotomab satetraxetan) at the 32nd Annual Congress of the European Association of Nuclear Medicine (13-17 October 2018, Düsseldorf, Germany).

The presentations are:

Therapeutic efficacy of 177Lu-lilotomab satetraxetan in non-Hodgkin B-cell Lymphoma is controlled by G2/M cell cycle progression
Authors: A. Pichard et al.
Session: 305 - M2M: Therapy Effects, Preclinical
Abstract No. OP-069
Format: Oral presentation

Date/time: Sunday 14 October, 11:30-12:45 CEST

Tumor Absorbed Dose and Changes in FDG PET Parameters in Non-Hodgkin Lymphoma Patients Treated with 177Lu-lilotomab satetraxetan

Authors: A. Løndalen et al.
Session: 608 - Clinical Oncology - Rapid Fire Session: It´s in the Blood!
Abstract No. OP-252
Format: Oral presentation

Date/time: Monday 15 October, 08:00-09:30 CEST


About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.


SOURCE Nordic Nanovector

Molecular Imaging Homepage